Reuters logo
BRIEF-Pfizer and Sangamo updates on early stage trial on its blood disorder therapy
August 25, 2017 / 3:52 PM / a month ago

BRIEF-Pfizer and Sangamo updates on early stage trial on its blood disorder therapy

Aug 25 (Reuters) - Pfizer Inc:

* Sangamo and Pfizer announce first patient receives treatment in Phase 1/2 clinical trial evaluating SB-525 investigational gene therapy for Hemophilia A Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below